Quest Diagnostics Incorporated (DGX.MX)
- Previous Close
2,458.05 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 2,458.05 - Volume
0 - Avg. Volume
0 - Market Cap (intraday)
272.981B - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
20.49 - EPS (TTM)
119.95 - Earnings Date Apr 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Apr 5, 2024
- 1y Target Est
--
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
www.questdiagnostics.com40,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DGX.MX
Performance Overview: DGX.MX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DGX.MX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DGX.MX
Valuation Measures
Market Cap
237.52B
Enterprise Value
319.26B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
34.51
Enterprise Value/EBITDA
184.33
Financial Highlights
Profitability and Income Statement
Profit Margin
9.23%
Return on Assets (ttm)
6.21%
Return on Equity (ttm)
14.62%
Revenue (ttm)
9.25B
Net Income Avi to Common (ttm)
850M
Diluted EPS (ttm)
119.95
Balance Sheet and Cash Flow
Total Cash (mrq)
686M
Total Debt/Equity (mrq)
85.66%
Levered Free Cash Flow (ttm)
662.88M